Abdelaziz Lobna A, Ebian Huda F, Harb Ola A, Nosery Yousef, Taha Heba F, Nawar Nashwa
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Contemp Oncol (Pozn). 2022;26(1):78-87. doi: 10.5114/wo.2022.115678. Epub 2022 Mar 30.
Cytokeratin 19 (CK19) is highly expressed in epithelial tumours such as breast cancer (BC). Octamer-binding transcription factor 4 (OCT4), a transcription factor of the POU (Pit-Oct-UNC) family, plays a criti-cal role in the self-renewal and maintenance of pluripotency of embryonic stem cells; therefore, it has been used as a promising CSC marker.
CK19 was assessed in peripheral blood using flow-cytometric analysis while OCT4 was evaluated in breast tissue samples by immunohistochemistry from 70 patients (non-metastatic BC, meta-static BC, and non-malignant breast tumours).
CK19 and OCT4 were significantly associated with BC patients compared to control ( < 0.001). CK19 was detected in 38 patients with BC (62.2%); meanwhile, OCT4 was positive in 37 BC patients (60.6%). CK19 was positively associated with grade ( = 0.002), HER2 ( = 0.009), metastasis ( = 0.026), molecular subtypes and LN ( < 0.001), and stage ( = 0.001) while OCT4 expression was positively associated with BMI ( < 0.023), aggressive molecular subtype ( < 0.019), ER expression ( = 0.025), presence of LN metastases ( < 0.017), and distant metastasis ( < 0.018). A non-significant relation was found between the expression of CK19 and OCT ( = 0.291). The positive expression of CK19 and OCT4 was significantly and inversely associated with both 3-year OS and 3-year PFS.
CK19 and OCT4 are associated with BC, so they can be considered as prognostic and predictive markers for poor OS and PFS in non-metastatic as well as metastatic BC patients.
细胞角蛋白19（CK19）在诸如乳腺癌（BC）等上皮性肿瘤中高表达。八聚体结合转录因子4（OCT4）是POU（Pit-Oct-UNC）家族的一种转录因子，在胚胎干细胞的自我更新和多能性维持中起关键作用；因此，它已被用作一种有前景的癌症干细胞（CSC）标志物。
采用流式细胞术分析评估外周血中的CK19，同时通过免疫组织化学对70例患者（非转移性BC、转移性BC和非恶性乳腺肿瘤）的乳腺组织样本进行OCT4评估。
与对照组相比，CK19和OCT4在BC患者中显著相关（P<0.001）。38例BC患者（62.2%）检测到CK19；同时，37例BC患者（60.6%）OCT4呈阳性。CK19与分级（P = 0.002）、HER2（P = 0.009）、转移（P = 0.026）、分子亚型和淋巴结（P<0.001）以及分期（P = 0.001）呈正相关，而OCT4表达与体重指数（P<0.023）、侵袭性分子亚型（P<0.019）、雌激素受体（ER）表达（P = 0.025）、淋巴结转移的存在（P<0.017）和远处转移（P<0.018）呈正相关。CK19和OCT之间未发现显著关系（P = 0.291）。CK19和OCT4的阳性表达与3年总生存期（OS）和3年无进展生存期（PFS）均显著负相关。
CK19和OCT4与BC相关，因此它们可被视为非转移性以及转移性BC患者OS和PFS较差的预后和预测标志物。
